Patrick Soon-Shiong, Chairman of Chan Soon-Shiong Family Foundation, Executive Chairman at ImmunityBio, Executive Chairman of Los Angeles Times, shared a post on X:
“Since 2016 we proposed to the FDA and completed trials across multiple tumor types ImmunityBio to address the hypothesis that by stimulating the NK cells and T cells we can convert cancer into a chronic disease with long-term survival regardless of tumor types. Current standards of care of high-dose chemotherapy and radiation counter intuitively wipe out the very cells in our body that kill cancer. To prove this hypothesis, we initiated multiple trials across multiple tumor types and found complete responses in Merkel cell, triple negative, pancreatic, head and neck cancers proving to ourselves that this hypothesis of protecting the immune system is the path to long term survival and turning cancer from a painful disease to one with high quality of life.
The diagram I drew below for the Biden administration and Big Pharma and FDA in which we held a meeting at Vice President’s Biden residence to describe this hypothesis and drive the collaborative effort we called ‘Cancer Manhattan Project’ to win the war against cancer and to understand the need for a paradigm change of how we treat cancer and how we would launch Cancer Moonshot.
For some reason, Vice President Biden and Big Pharma pulled out of our Cancer MoonShot. Biden and Collins went along with their own cancer moonshot involving Big Pharma and academia. So without any support from the Biden and Collins administration we pursued our trials and our moonshot alone at our cost with our BioShield platform.
So from 2020 to 2024 we tested our approach in 100s of patients with all types of cancer who failed all standards of care..very late advanced stages. All the BioShield therapies were administered as outpatients.
For the number of tumor types and countless Phase 2 studies, see ClinicalTrials.gov and search ImmunityBio.
These trials and the protocols administered addressed the diagram below to prove my version of the concept of what I called ‘Quantum Oncotherapeutics’– the cells in the tumors have quantum lives… from killers to suppressors… we need to activate the killers and suppress the suppressors… the target is the immune system and the power is within us where by treating the immune system our killer cells within kills the cancer.
After almost a MILLION PAGES of filings with the FDA Anktiva was approved in 2024 for bladder cancer. But our trials showed the same prolonged survival (paper being submitted now) was achieved when we rescued the ALC count (NK and T cells) by addressing lymphopenia with our IL-15 injection of ANKTIVA. This result was noted across multiple tumor types and here we are now in 2025 with the clinical knowledge that the paradigm change for cancer treatment and the path to the cure is at hand.
The results after decades of study and QUILT clinical trials now confirm that we were correct: the root cause of cancer is the collapse of the immune system and that we have the power within ourselves by re-activating the NK and T cells with our IL-15 protein injection now fondly named the Bioshield (ANKTIVA).
But the goal is to generate memory T cells and memory NK cells for long term duration freedom from cancer… we have shown this in over 10 different cancers in patients who have failed all standards of care.
Our goal now to treat cancer earlier in the disease or even treat patients before they get cancer. We are proud to say that the trial with NCI in Lynch syndrome (cancer free patients with a 80 percent higher risk of getting cancer) is now fully recruited… a cancer prevention trial.
The BioShield is not a single shot but a careful orchestration of a platform of subcutaneous injection of IL-15 ANKTIVA plus NK cells to outsmart the tumor.
It is complex but all given in an outpatient setting…we are trying hard for the large cancer centers to understand this protocol in the figure below and the ‘Founders vision.'”
You can also read: Patrick Soon-Shiong: Complete Responses with NK Cell Therapy – the Power of the Bioshield Platform
